Vistagen submits study protocol for treatment of adjustment disorder with anxiety related to covid-19

Vistagen submits ph94b phase 2a study protocol for treatment of adjustment disorder with anxiety related to the covid-19 pandemic through u.s. fda's coronavirus treatment acceleration program (ctap).vistagen therapeutics - proposed phase 2a study will be conducted in new york city on open-label basis, involve about 30 patients.
VTGN Ratings Summary
VTGN Quant Ranking